Metabolic Health
GLP-1 and Inflammation
Semaglutide measurably lowers a key inflammation marker in trial data, independent of how much weight is lost. Here is w...
The cardiovascular finding is the most important thing established about this drug class, and it is the reason they are now discussed as cardiometabolic medicines rather than weight loss products.
Here is what the trials showed, how the effect works, and who it actually applies to.
The SELECT trial
Published in the New England Journal of Medicine in 2023, SELECT enrolled adults aged 45 and over who had pre-existing cardiovascular disease and a BMI of 27 or above, but no history of diabetes.
Participants received once-weekly semaglutide 2.4 mg or placebo.
Semaglutide was superior to placebo in reducing the incidence of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.
The design choice that made this trial matter was excluding diabetes. Every previous cardiovascular finding for this drug class came from diabetes populations, where benefit could reasonably be attributed to blood sugar control. SELECT removed that explanation.
The earlier diabetes evidence
The pattern was established before SELECT.
LEADER, published in the New England Journal of Medicine in 2016, followed 9,340 people with type 2 diabetes at high cardiovascular risk on liraglutide. The combined outcome of cardiovascular death, non-fatal heart attack and non-fatal stroke occurred in 13.0 percent against 14.9 percent on placebo, a hazard ratio of 0.87.
REWIND followed 9,901 people on dulaglutide for a median 5.4 years, with events occurring 594 times against 663 on placebo. Notably, most participants did not have established cardiovascular disease at enrolment, extending benefit to primary prevention.
SUSTAIN-6 examined semaglutide's cardiovascular outcomes in type 2 diabetes.
Different drugs, different populations, consistent direction.
How the benefit works
Several mechanisms operate together, and most run through weight reduction.
Blood pressure falls. Hypertension is among the largest contributors to heart attack and stroke. Weight loss lowers it, frequently enough that existing blood pressure medication needs reducing.
Lipids improve. Triglycerides fall and the overall lipid picture improves.
Blood sugar improves, even in people without diabetes. Insulin resistance contributes to arterial damage.
Inflammation reduces. Excess fat tissue, particularly visceral fat around the organs, is metabolically active and produces inflammatory signals. Atherosclerosis is substantially an inflammatory process.
Visceral fat falls preferentially. The fat around your organs is the metabolically dangerous kind, and it responds well to weight loss.
Possible direct effects. GLP-1 receptors exist in heart and blood vessel tissue. Whether activating them contributes independently of weight loss is not settled, though some analyses suggest the benefit exceeds what weight reduction alone would predict.
Who this applies to
This is where precision matters, because the finding is frequently over-generalised.
Established: adults with existing cardiovascular disease and overweight or obesity. That is who SELECT enrolled. For that group, the evidence is strong.
Also established: people with type 2 diabetes at cardiovascular risk, from LEADER, REWIND and SUSTAIN-6.
Not established: healthy younger adults with modest excess weight and no cardiovascular disease. Nobody has run that trial, and extrapolating is not evidence.
Someone at 32 with a BMI of 29 and normal blood pressure should not assume SELECT describes them. The benefit shown was in a higher-risk population where there was more risk to reduce.
The South Asian dimension
Worth stating because it changes the risk assessment here.
South Asian populations develop cardiovascular disease at younger ages and at lower BMI thresholds than Western populations. Body composition differs, with a greater tendency toward visceral fat at any given weight.
Some guidance uses lower BMI cut-offs for South Asian populations for exactly this reason, with overweight and obesity thresholds set below the standard 25 and 30.
The practical implication is that a Pakistani adult at a BMI that looks unremarkable by Western standards may carry more cardiometabolic risk than the number suggests.
Confirm your starting BMI, and treat it as one input rather than the whole picture. Waist circumference and blood pressure matter alongside it.
What this means for the decision
The cardiovascular finding shifts what treatment is for.
If your concern is appearance, the scale is the measure. If you have cardiovascular disease, hypertension or prediabetes alongside excess weight, the relevant outcomes are events avoided rather than kilograms lost.
That reframing also explains why the 5 to 10 percent threshold matters. Blood pressure, lipids and inflammation improve in that range. You do not need to reach a target weight to move the risk.
METASLIM™ GLP-1 pathway support works through the same appetite pathway as a physician-reviewed sublingual supplement, with physician review before dispatch. It is not semaglutide, and SELECT describes semaglutide rather than this product. Nobody should present it as producing SELECT outcomes.
What carries across is the principle. Cardiovascular improvement follows from weight reduction, blood pressure change and reduced visceral fat, and those follow from eating less regardless of the route.
Anyone with existing cardiovascular disease should be making treatment decisions with a cardiologist or physician who knows their history, not independently.
Our guide to GLP-1 benefits beyond weight loss covers the wider picture, and long-term safety covers the risk side.
The summary
SELECT enrolled adults aged 45 and over with pre-existing cardiovascular disease and BMI 27 or above but without diabetes, and found semaglutide reduced cardiovascular death, non-fatal heart attack and non-fatal stroke.
LEADER, REWIND and SUSTAIN-6 established the same direction in type 2 diabetes populations.
The mechanisms are lower blood pressure, improved lipids and blood sugar, reduced inflammation and preferential loss of visceral fat.
The benefit is established in higher-risk populations, not in healthy younger adults with modest excess weight.
South Asian populations develop cardiovascular disease at lower BMI thresholds, so the number understates risk here.
Review the full program details and discuss cardiovascular history at the review.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.